Engineering hope: a founder’s letter to US investors
Since 2025, this work has been my life — every day, around the clock. What drives me is not abstract. It is the people fighting cancer, and one hard conviction: human empathy, however essential, has to be matched by rigorous engineering.
A problem this serious cannot rely on improvisation. It demands disciplined, measurable engineering applied to the most complex system we know — the human body. That conviction shaped our research direction.
We are studying how the pharmacodynamic potential of Amazonian endemic compounds can be paired with a Red Laser (660 nm) architecture. Our engineering hypothesis is that targeted red light can act like a precise ignition key — helping to activate and concentrate the action of our compounds within the tumor microenvironment, rather than losing it across the whole system. To be clear: this is a research-and-development hypothesis under preclinical, laboratory study. It is not a proven clinical treatment, and nothing here is a promise of a medical result.
Our discipline is engineering discipline. We have worked to digitize our process and to pursue reproducibility and stability of these biochemical reactions as a concrete, measurable target — moving step by step from experimental chemistry toward a documented, repeatable methodology we think of as precision biomechanics.
Today we open a new chapter. We are seeking strategic partners in the US market — not capital alone, but laboratories and operators who can help take a rigorous methodology toward a recognized standard. Until now, the architecture of our bioengineering synthesis has been confidential. Under appropriate confidentiality, we are prepared to share our methodology and intellectual property for technical due diligence — exactly how candidate agents pass our filters of chemical profiling, pharmacodynamics, and hardware compatibility — and to integrate our IP with the capabilities of US biotech laboratories.
We are building this alongside the standard of care — never as a replacement for it. The next standard will be earned with evidence, and in partnership. If that mission resonates with you, let’s build it together.